Overview

A 680-gene panel focused on lung cancer provides substantial breadth for understanding acquired resistance when a targeted regimen loses effect. Lung tumors are notorious for developing bypass mechanisms, and a large gene set improves the odds of catching the responsible alteration. This article discusses how such a panel, paired with circulating tumor DNA monitoring, supports rebiopsy and treatment redirection.

Why Breadth Matters in Resistance

When a lung cancer progresses on a targeted drug, the escape route may be a new fusion, a copy-number shift, or activation of a parallel pathway. A 680-gene panel surveys a wide oncogenic landscape, so these events are more likely to fall within coverage than with a small hotspot test. Broader coverage translates into a higher chance of finding an actionable change rather than a dead end.

Tissue Rebiopsy Versus Liquid Biopsy

Resistance testing can use a fresh tissue rebiopsy or a plasma ctDNA sample. Tissue gives architectural and subclonal detail but is invasive and sometimes unavailable; ctDNA is less burdensome and can reflect multiple lesions at once. A 680-gene panel is often applied to both inputs, with ctDNA used for rapid screening and tissue reserved for when a definitive histological correlate is needed.

Acting on the Result

A detected resistance mechanism points to a concrete next step: a different targeted agent, combination, or switch to chemotherapy or immunotherapy depending on the alteration and prior lines. The baseline broad profile also serves as a reference, so newly emergent changes are easier to recognize against the original architecture. Even when no target is found, the negative result helps avoid futile therapy.

Coordination between the molecular report and imaging matters as well. Radiologic progression sometimes precedes a detectable molecular change, and a negative ctDNA result during early progression may simply reflect low shed. Correlating the 680-gene findings with imaging and clinical status prevents over-reading a single negative, and supports the decision to obtain tissue when the liquid result is inconclusive or when a histological correlate would change management.

FAQ

Q: How does a 680-gene panel help with resistance? A: Its wide coverage increases the likelihood of detecting the specific bypass mutation, fusion, or copy-number change driving progression.

Q: Is ctDNA enough, or is rebiopsy needed? A: ctDNA is less invasive and reflects multiple sites, but tissue rebiopsy provides histological detail when a definitive correlate is required.

Q: Can the panel guide the next treatment? A: Yes. An identified resistance mechanism can support switching to another targeted agent, a combination, or a different modality.

Q: What if no resistance change is found? A: A negative result still helps by ruling out known mechanisms and avoiding therapies unlikely to work. It also documents the molecular state at progression, which can inform trial eligibility and supports a pragmatic switch to established regimens when no targetable escape route is evident.